Virology: Complete replication of hepatitis C virus in cell culture

Science

Volumn 309, Issue 5734, 2005, Pages 623-626

  Lindenbach, Brett D ^a   Evans, Matthew J ^a   Syder, Andrew J ^a   Wölk, Benno ^a   Tellinghuisen, Timothy L ^a   Liu, Christopher C ^b   Maruyama, Toshiaki ^c,d   Hynes, Richard O ^b   Burton, Dennis R ^c   McKeating, Jane A ^a,e   Rice, Charles M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d Alexion Antibody Technologies Inc   (United States)

^e UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; CELL CULTURE; GENES; LIFE CYCLE; PROTEINS;

CELLULAR EXPRESSION; GLYCOPROTEINS; PATHOGEN; VITRO SYSTEM;

VIRUSES;

ALPHA INTERFERON; ANTIVIRUS AGENT; GLYCOPROTEIN E; MONOCLONAL ANTIBODY; CD81 ANTIGEN; GLYCOPROTEIN E2, HEPATITIS C VIRUS; LEUKOCYTE ANTIGEN; NS 5 PROTEIN, HEPATITIS C VIRUS; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VIRUS RNA;

MEDICINE;

ARTICLE; CELL CULTURE; GENOME ANALYSIS; HEPATITIS C VIRUS; IN VITRO STUDY; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS GENOME; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN; BIOSYNTHESIS; CULTURE MEDIUM; DENSITY GRADIENT CENTRIFUGATION; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MUTATION; PHYSIOLOGY; REPLICON; SERODIAGNOSIS; TUMOR CELL LINE; VIRION; VIRUS CULTURE;

HEPATITIS C VIRUS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIGENS, CD; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CENTRIFUGATION, DENSITY GRADIENT; CULTURE MEDIA, CONDITIONED; GENOME, VIRAL; HEPACIVIRUS; HUMANS; INTERFERON-ALPHA; MUTATION; NEUTRALIZATION TESTS; REPLICON; RNA, VIRAL; SERIAL PASSAGE; TRANSFECTION; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS; VIRION; VIRUS CULTIVATION; VIRUS REPLICATION;

EID: 23044437222     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1114016     Document Type: Article

References (29)

1. Anonymous, Wkly. Epidemiol. Rec. 75, 18 (2000).
2. K. J. Blight, A. A. Kolykhalov, C. M. Rice, Science 290, 1972 (2000).
3. T. Date et al., J. Biol. Chem. 279, 22371 (2004).
4. T. Kato et al., Gastroenterology 125, 1808 (2003).
5. V. Lohmann et al., Science 285, 110 (1999).
6. K. J. Blight, J. A. McKeating, C. M. Rice, J. Virol. 76, 13001 (2002).
7. J. Bukh et al., Proc. Natl. Acad. Sci. U.S.A. 99, 14416 (2002).
8. T. Pietschmann et al., J. Virol. 76, 4008 (2002).
9. Materials and methods are available as supporting material on Science Online.
10. E. V. Agapov et al., J. Virol. 78, 2414 (2004).
11. B. M. Kümmerer, C. M. Rice, J. Virol. 76, 4773 (2002).
12. P. Pileri et al., Science 282, 938 (1998).
13. B. Bartosch et al., J. Biol. Chem. 278, 41624 (2003).
14. E. G. Cormier et al., Proc. Natl. Acad. Sci. U.S.A. 101, 7270 (2004).
15. J. Zhang et al., J. Virol. 78, 1448 (2004).
16. R. Bartenschlager, M. Frese, T. Pietschmann, Adv. Virus Res. 63, 71 (2004).
17. D. Bradley et al., J. Med. Virol. 34, 206 (1991).
18. N. Fujita et al., J. Med. Virol. 63, 108 (2001).
19. T. Heller et al., Proc. Natl. Acad. Sci. U.S.A. 102, 2579 (2005).
20. M. Hijikata et al., J. Virol. 67, 1953 (1993).
21. D. Lamarre et al., Nature 426, 186 (2003).
22. A. K. Saksena et al., International Patent Application WO 02/008244 (2002).
23. K. Lin, A. D. Kwong, C. Lin, Antimicrob. Agents Chemother. 48, 4784 (2004).
24. S. S. Carroll et al., J. Biol. Chem. 278, 11979 (2003).
25. T. Wakita, T. Kato, T. Date, M. Miyamoto, paper presented at the 11th International Symposium on HCV and Related Viruses, Heidelberg, Germany, 5 October 2004.
26. T. Wakita et al., Nat. Med. 12 June 2005 (10.1038/nm1268).
27. J. Zhong et al., Proc. Natl. Acad. Sci. U.S.A. 6 June 2005 (10.1073/pnas.0503596102).
28. T. Pietschmann et al., paper presented at the 11th International Symposium on HCV and Related Viruses, Heidelberg, Germany, 5 October 2004.
29. We thank P. Holst, V. Kramer, and N. Torres for technical assistance; J. Bloom, A. Gauthier, L. Dustin, and D. Bernard for careful review of the manuscript; T. Wakita for SGR-JFH1, SGR-JFH (H2476L), and SGR-JFH(GND); J. Bukh for pJ6CF; D. Moradpour for C7-50 antibody; T. von Hahn and J. Zhang for HepG2/CD81 cells; Boehringer Ingelheim for BILN 2061; The Schering-Plough Research Institute for SCH6; C. Lin and A. Kwong of Vertex Pharmaceutical, Inc. for PI-1; and D. Olsen and S. Ludmerer at Merck for 2′C-methyladenosine. Funded by grants from NIH (CA57973, CA85883, AI40034 to C.M.R., CA10702 to B.D.L., DK70497 to A.J.S., AI51820 to T.L.T., AI50798 to J.A.M.) and the Greenberg Medical Research Institute. Additional support was provided by the Charles H. Revson Foundation (M.J.E.) and the German Science Foundation (Deutsche Forschungsgemeinschaft) (B.W.). B.D.L. is a recipient of the National Cancer Institute Howard Temin Award. C.M.R. is a manager of and has equity in Apath, LLC, which has an exclusive license for the Huh-7.S cell line.